Trishula

Trishula Therapeutics, a spinout from Tizona, is a clinical-stage antibody company focused on immunotherapy. Its first-in-class anti-CD39 program (TTX-030) is partnered with AbbVie and has demonstrated promising data in Phase 1/1b clinical trials as a monotherapy and in combination with an anti-PD-1 agent and standard chemotherapy in adults with advanced cancers. TTX-030 is currently undergoing a randomized phase 2 study in frontline metastatic pancreatic cancer.